March 14, 2012 - Update on Peripheral T-Cell Lymphoma
Your order contains item(s) View Order
- Peripheral T-cell lymphoma (PTCL)
- PTCL subtypes
- Treatment options for patients with newly diagnosed and refractory or relapsed PTCL
- The role of clinical trials as treatment options for PTCL patients
- PTCL information and support resources for patients, caregivers and healthcare professionals
Steven M. Horwitz, MD
Assistant Attending, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY
Questions Asked by the PTCL Community
- Is there any relationship between sarcoidosis (an inflammatory disease) and PTCL? Is it possible to confuse the diagnoses?
- Is it true that how you feel after the first cycle of chemotherapy (what side effects you have) is how you will feel during the rest of cycles?
- With autologous transplant, is the survival rate now any better than it used to be?
- Are there any new drugs for PTCL on the horizon?
- If the disease comes back, is getting another biopsy necessary to understand how to best treat it?
- Is it true that young male patients treated for inflammatory bowel disease (IBD) are at risk of developing hepatosplenic T-cell lymphoma, and is it because of the treatment for IBD? And if so, how can that risk be reduced?
- What is the relationship between Epstein-Barr virus and PTCL?
- Can you explain the diagnosis of PTCL with a cytotoxic T-cell phenotype?
- Where does rituximab (Rituxan®) fit into PTCL treatment?
- What is the cure rate for stage IV lymphoblastic lymphoma? Are there any new drugs on the horizon?
- What would be the best treatment for pediatric ALK-positive anaplastic large cell lymphoma?
- What are the chances of relapse after being in remission following an autologous transplant?